2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-145604
    Vicasinabin 1433361-02-4 98.37%
    Vicasinabin (RG7774) is an orally active, selective, and full CB2R agonist, with EC50 values of 2.81 nM and 2.60 nM for human CB2R and mouse CB2R, respectively. Vicasinabin inhibits inflammation, reduces leukocyte adhesion and decreases vascular permeability by selectively activating CB2R. Vicasinabin can be used in the researches for diabetic retinopathy, uveitis and laser-induced choroidal neovascularization.
    Vicasinabin
  • HY-145686
    AV023 1107710-62-2 99.31%
    AV023 is a potent inhibitor of ANKRD22. AV023 promotes the expansion of gastrointestinal mucosal epithelial stem cells and indirectly activates the Wnt classical pathway, which helps the recovery of damaged gastrointestinal mucosal tissues in the body (extracted from patent CN111205231B).
    AV023
  • HY-145728
    Alicaforsen 185229-68-9
    Alicaforsen is an oligonucleotide and immunostimulant targeting human ICAM-1 mRNA. Alicaforsen hybridizes to specific sites to reduce the expression level of ICAM-1. Alicaforsen is applicable to relevant research on psoriasis, rheumatoid arthritis and inflammatory bowel disease.
    Alicaforsen
  • HY-145960
    MC-Val-Cit-PAB-Amide-TLR7 agonist 4 2413016-49-4 99.39%
    MC-Val-Cit-PAB-Amide-TLR7 agonist 4 (example 15) is a HER2-TLR7 and HER2-TLR8 immune agonist conjugate.
    MC-Val-Cit-PAB-Amide-TLR7 agonist 4
  • HY-146054
    CXCR4 modulator-2 2554877-43-7 98%
    CXCR4 modulator-2 (compound Z7R) is a highly potent CXCR4 modulator with an IC50 value of 1.25 nM. CXCR4 modulator-2 has acceptable stability (t1/2 = 77.1 min) in mouse serum and exhibits anti-inflammatory activity in mouse edema model.
    CXCR4 modulator-2
  • HY-146231
    SS47 2636072-62-1 98%
    SS47, a PROTAC-based HPK1 degrader, exerts proteasome-mediated HPK1 degradation. The degradation of HPK1 via SS47 also significantly enhances the antitumor efficacy.
    SS47
  • HY-146564
    R-HP210 3034696-14-2 98.21%
    R-HP210 acts on the NF-κB mediated tethered transrepression function (IC50=3.80 μM). R-HP210 represses the LPS-induced transcription of a variety of proinflammatory genes such as IL-1β, IL-6 and COX-2. R-HP210 does not induce the transactivation functions of Glucocorticoids (GCs).
    R-HP210
  • HY-14658S
    Thalidomide-d4 1219177-18-0 98.71%
    Thalidomide-d4 is a deuterium labeled Thalidomide. Thalidomide inhibits cereblon (CRBN), a part of the cullin-4 E3 ubiquitin ligase complex CUL4-RBX1-DDB1, with a Kd of ~250 nM, and has immunomodulatory, anti-inflammatory and anti-angiogenic cancer properties.
    Thalidomide-d4
  • HY-146971
    Anti-inflammatory agent 38 3032633-42-1 98.66%
    Anti-inflammatory agent 38 (compound 23d) is a potent Nrf2/HO-1 pathway inhibitor, with an IC50 value of 0.38 μM for NO. Anti-inflammatory agent 38 can significantly reduce the level of ROS in cells. Anti-inflammatory agent 38 can be used for researching anti-inflammatory.
    Anti-inflammatory agent 38
  • HY-147055
    THR-β agonist 5 2542029-74-1 99.89%
    THR-β agonist 5 is a THR-β agonist. THR-β agonist 5 can be used for the research of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis.
    THR-β agonist 5
  • HY-147086
    CAY10789 123226-28-8 99.84%
    CAY10789 is a potent CysLT1R (cysteinyl leukotriene receptor 1) antagonist (IC50=2.80 μM) and GPBAR1 (G-protein-coupled bile acid receptor 1) agonist (EC50=3 μM). CAY10789 significantly reduces the adhesion of U937 cells to HAEC, reduces the expression of TNF-α. CAY10789 shows very promising metabolic stability and excellent pharmacokinetics. CAY10789 can be used for the research of colitis, metabolic syndromes, and other GPBAR1/CysLT1R-related diseases.
    CAY10789
  • HY-147179
    INX-SM-56 2734878-18-1 99.47%
    INX-SM-56 is a cytotoxin that can be used for the synthesis of anti-VISTA antibody agent conjugate. VISTA: V-region Immunoglobulin-containing Suppressor of T cell Activation.
    INX-SM-56
  • HY-147377
    N-Salicyloyltryptamine 31384-98-2
    N-Salicyloyltryptamine acts on voltage-dependent Na+, Ca2+, and K+ ion channels inhibitor. N-Salicyloyltryptamine inhibits K+ currents with an IC50 value of 34.6 μM (Ito). N-Salicyloyltryptamine also exhibits anticonvulsant, anti-inflammatory, analgesic, and vasorelaxation effect-.
    N-Salicyloyltryptamine
  • HY-147385
    CCR4 antagonist 3 1957-01-3 99.94%
    CCR4 antagonist 3 is a potent chemokine receptor 4 (CCR4) antagonist with an IC50 value of 1.7 μM for [125I]TARC (thymus and activation regulated chemokine). CCR4 antagonist 3 inhibits binding of radiolabeled TARC and macrophage-derived chemokine (MDC) to CCR4 receptors on the surface of CEM cells. CCR4 antagonist 3 also inhibits the in vitro migration of CEM cells mediated by TARC (IC50 = 6.4 μM).
    CCR4 antagonist 3
  • HY-148051
    Ilaprazole sulfone 172152-37-3 99.77%
    Ilaprazole sulfone is the major metabolite of Ilaprazole (HY-101664), is predominantly catalysed by CYP3A4/5. Ilaprazole (IY-81149) is an orally active proton pump inhibitor.
    Ilaprazole sulfone
  • HY-148134
    5-LOX-IN-1 55040-82-9 98.04%
    5-LOX-IN-1 (compound 2b) is an inhibitor of human 5-Lipoxygenase (5-LOX) with an IC50 value of 2.3 μM. 5-LOX-IN-1 can be used for the research of inflammation.
    5-LOX-IN-1
  • HY-148181
    c-Fms-IN-13 885704-58-5 99.27%
    c-Fms-IN-13 (compound 14) is a potent FMS kinase inhibitor with an IC50 value of 17 nM. c-Fms-IN-13 can be used as an anti-inflammatory agent.
    c-Fms-IN-13
  • HY-148187
    NLRP3-IN-11 2769040-91-5 98.79%
    NLRP3-IN-11 is a NLR family pyrin domain containing 3 (NLRP3) proteins inhibitor. NLRP3-IN-11 has biological activity for NLRP3 with an IC50 value of <0.3 μM. NLRP3-IN-11 can be used for the researh of inflammatory and degenerative diseases including NASH, atherosclerosis and other cardiovascular diseases, Alzheimer's disease, Parkinson's disease, diabetes, gout, and numerous other autoinflammatory diseases.
    NLRP3-IN-11
  • HY-148238
    GNE-2256 2102170-43-2 99.14%
    GNE-2256 (molecule 19), a chemical probe, is an orally active IRAK4 (Interleukin 1 receptor associated kinase 4) inhibitor (IRAK4 Ki=1.4 nM; IL-6 IC50=190 nM).
    GNE-2256
  • HY-148292
    C16-Sphingosine-1-phosphate 709026-60-8 99.9%
    C16-Sphingosine-1-phosphate is a derivative of Sphingosine-1-phosphate and also an endogenous ligand for the EDG/S1P receptor. C16-Sphingosine-1-phosphate can be used in the research of angiogenesis, inflammation, and cardiovascular diseases.
    C16-Sphingosine-1-phosphate
Cat. No. Product Name / Synonyms Application Reactivity